Repare Therapeutics Inc
RPTX2.140USD
-0.010-0.47%
收盤 12/19, 16:00（美東）報價延遲15分鐘
91.99M總市值
虧損本益比TTM
關於 Repare Therapeutics Inc 公司
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc簡介
公司代碼RPTX
公司名稱Repare Therapeutics Inc
上市日期Jun 19, 2020
CEOForte (Steve)
員工數量129
證券類型Ordinary Share
年結日Jun 19
公司地址7210 Frederick-Banting, Suite 100
城市ST-LAURENT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編H4S 2A1
電話18574127018
網址https://www.reparerx.com/
公司代碼RPTX
上市日期Jun 19, 2020
CEOForte (Steve)
Repare Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
31.62K
+6.75%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
+8.59%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
31.62K
+6.75%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
+8.59%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月18日 週四
更新時間: 12月18日 週四
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
23.97%
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
其他
54.51%
持股股東
持股股東
佔比
BVF Partners L.P.
23.97%
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
其他
54.51%
股東類型
持股股東
佔比
Hedge Fund
29.48%
Investment Advisor/Hedge Fund
10.95%
Investment Advisor
8.96%
Private Equity
7.51%
Individual Investor
0.41%
Venture Capital
0.31%
Research Firm
0.17%
Family Office
0.09%
其他
42.13%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
10.33M
24.05%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
3.44M
8.02%
+71.16K
+2.11%
Jun 30, 2025
OrbiMed Advisors, LLC
3.32M
7.73%
+122.13K
+3.82%
Jun 30, 2025
Redmile Group, LLC
1.59M
3.69%
-298.21K
-15.83%
Jun 30, 2025
MPM Capital Inc.
1.12M
2.61%
--
--
Jun 30, 2025
MPM BioImpact LLC
819.92K
1.91%
--
--
Jun 30, 2025
Renaissance Technologies LLC
522.86K
1.22%
+224.20K
+75.07%
Jun 30, 2025
Citadel Advisors LLC
937.49K
2.18%
--
--
Jun 30, 2025
Rangeley Capital LLC
355.29K
0.83%
+355.29K
--
Jun 30, 2025
Acadian Asset Management LLC
681.18K
1.59%
+40.85K
+6.38%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Avantis US Equity ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Repare Therapeutics Inc的前五大股東是誰？
Repare Therapeutics Inc的前五大股東如下：
BVF Partners L.P.持有股份：10.33M佔總股份比例：24.05%。
Blue Owl Capital Holdings LP持有股份：3.44M佔總股份比例：8.02%。
OrbiMed Advisors, LLC持有股份：3.32M佔總股份比例：7.73%。
Redmile Group, LLC持有股份：1.59M佔總股份比例：3.69%。
MPM Capital Inc.持有股份：1.12M佔總股份比例：2.61%。
BVF Partners L.P.持有股份：10.33M佔總股份比例：24.05%。
Blue Owl Capital Holdings LP持有股份：3.44M佔總股份比例：8.02%。
OrbiMed Advisors, LLC持有股份：3.32M佔總股份比例：7.73%。
Redmile Group, LLC持有股份：1.59M佔總股份比例：3.69%。
MPM Capital Inc.持有股份：1.12M佔總股份比例：2.61%。
Repare Therapeutics Inc的前三大股東類型是什麼？
Repare Therapeutics Inc 的前三大股東類型分別是：
BVF Partners L.P.
Blue Owl Capital Holdings LP
OrbiMed Advisors, LLC
BVF Partners L.P.
Blue Owl Capital Holdings LP
OrbiMed Advisors, LLC
有多少機構持有Repare Therapeutics Inc(RPTX)的股份？
截至2025Q3，共有151家機構持有Repare Therapeutics Inc的股份，合計持有的股份價值約為27.75M，占公司總股份的64.60% 。與2025Q2相比，機構持股有所增加，增幅為-7.57%。
哪個業務部門對Repare Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Repare Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
